Ajax loader
By using our website, you agree to our use of cookies as described in Cookie Policy.

Can't find what you're looking for?

 

Be sure to Sign in to see all available content.

 

If you don't have an account, Register here.

Search results for:

USA/
RTX12RB6
August 20, 2013
Cancer patient Stew Scannell receives an intravenous dose of Lambrolizumab during a promising cancer...
Los Angeles, UNITED STATES
A cancer patient receives an intravenous dose of Lambrolizumab during a promising cancer treatment clinical...
Cancer patient Stew Scannell receives an intravenous dose of Lambrolizumab during a promising cancer treatment clinical trial at UCLA Medical Center in Los Angeles, California August 19, 2013. When Scannell was first diagnosed with brain metastases and an incurable melanoma, he was not expected to live long. Now he flies to Los Angeles from his home in Oklahoma every three weeks for injections of the drug Lambrolizumab, or MK-3475, from which he says he feels no negative side effects. He adds that the drug appears to help his body's immune system fight off his cancer cells, and testing indicates a significant reduction in the number and size of his cancers. He is now continuing to work and is helping some of his colleagues rebuild after their losses in the Oklahoma tornadoes earlier this year. REUTERS/David McNew (UNITED STATES - Tags: HEALTH SOCIETY SCIENCE TECHNOLOGY)
Sort by
Display
Items per page
Page
of 1